2013-12-16 12:46:43 - SADIF-Investment Analytics has applied its StockMarks™ stock-rating system to NovaBay Pharmaceuticals, Inc. (NBY) and produced a report, rating the company's attractiveness to long-term investors.
Ilhavo, Portugal - SADIF Investment Analytics, announces a new summary due diligence report covering NovaBay Pharmaceuticals, Inc. (NBY). The report uses SADIF's powerful StockMarks™ stock rating system and contains important analysis for any current or potential NovaBay Pharmaceuticals, Inc. investor.
Report Summary: NovaBay Pharmaceuticals, Inc. is a low quality company with a negative outlook. NovaBay Pharmaceuticals, Inc. has weak business growth and is run by inefficient management. The trend in NovaBay Pharmaceuticals, Inc. fair value exchange rate against its closest rated-competitor, XenoPort, Inc., has been appreciating over the past 2 weeks. When compared to its closest competitor, NovaBay Pharmaceuticals, Inc. shows similar undervaluation and is equally likely to underperform the market.
The report breaks down the Total StockMark into its three components
- business, management and price, performing an in-depth analysis of NovaBay Pharmaceuticals, Inc. for long-term investors.
The report has been distributed to Thomson Reuters. It is available in Investext and from multiple professional platforms including Thomson Research, Thomson ONE Banker, DIALOG/INTELLISCOPE, Thomson Gale, One source West Services, and Dow Jones/Factiva.
About SADIF-Investment Analytics:
SADIF-Investment Analytics is an independent investment research company covering 31 different markets and over 22,000 companies. The StockMarks rating system is based on proven investment principles and is designed to drive long-term shareholder returns.